Transplantation
Cold Spring Harbor, N.Y. - Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment.
Fulminant hepatic failure is a serious clinical disease and may threaten the life of patients. However, because of the damage of mass liver cells, the organ function is often irreversible due to the liver cell degeneration, swelling, or apoptosis. Thus, to supply new sources of functional liver cells is a valuable choice for these patients.
Updated guidelines on the diagnosis and management of heart failure will help physicians incorporate the latest research findings into the treatment of patients with this complex and disabling disease.
Sheffield, England - March 23, 2009 - Deafness affects more than 250 million people worldwide. It typically involves the loss of sensory receptors, called hair cells, for their "tufts" of hair-like protrusions, and their associated neurons.
DaVinci Biosciences, in collaboration with Luis Vernaza Hospital in Ecuador, announced today the publication of study results demonstrating the safety and feasibility of its acute and chronic spinal cord injury treatment platform in issue 17(12) of Cell Transplantation, a peer-reviewed journal focused on regenerative medicine. The study demonstrates that administering adult autologous bone marrow derived stem cells via multiple routes is feasible, safe, and most importantly, improves the quality of life for both acute and chronic spinal cord injury (SCI) patients.
CHICAGO (March 10, 2009) - New research published in the March issue of the Journal of the American College of Surgeons suggests that lung transplantation should be used with caution in patients older than 60 years and that the procedure is associated with high rates of mortality after one year in patients 70 and older.
A survey of physicians has found broad support for the position that parents should not bank their newborns' umbilical cord blood in a private blood bank unless another member of the family is at risk for a blood disease that will require a stem cell transplant.
An experimental procedure that dramatically strengthens stem cells' ability to regenerate damaged tissue could offer new hope to sufferers of muscle-wasting diseases such as myopathy and muscular dystrophy, according to researchers from the University of New South Wales (UNSW).
A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test, report scientists at The University of Texas Health Science Center at Houston in Nature Medicine's Advance Online Publication March 1.
Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back. A new study shows that they lack cellular immunity against the disease, making recurrence likely if antiviral treatment is withdrawn.
By now, most people have read stories about how to "grow your own organs" using stem cells is just a breakthrough away. Despite the hype, this breakthrough has been elusive.
There may be a new way to predict mortality in patients with idiopathic pulmonary fibrosis (IPF), a devastating disease that slowly petrifies the lungs. Most patients live only three years after diagnosis on average; however, some remain stable for many years, while for others, the disease progresses more rapidly.
Researchers from Northwestern University's Feinberg School of Medicine appear to have reversed the neurological dysfunction of early-stage multiple sclerosis patients by transplanting their own immune stem cells into their bodies and thereby "resetting" their immune systems.
A new study has found that transplantation of stem cells from the lining of the spinal cord, called ependymal stem cells, reverses paralysis associated with spinal cord injuries in laboratory tests.
Stem cell transplantation using umbilical cord blood is a standard treatment option for blood disorders in children, but not for adults, due to the difficulty of obtaining a sufficiently large dose of cells. To solve this problem, researchers from the University of Minnesota examined a new technique that combines two cord blood units from different donors for transplantation into adult or adolescent leukemia patients. Their study is to be published in the February 1, 2005, issue of Blood, the official journal of the American Society of Hematology.
